
Investments
41Portfolio Exits
15Funds
11Partners & Customers
4Service Providers
1About QHP Capital
QHP Capital manages private equity and other investments in the global biopharmaceutical sector, where its principal focus is investing in late-stage clinical assets and commercial-phase biopharmaceutical products. It contracts with global biopharmaceutical corporations to invest side-by-side in strategic development and commercialization programs. The company was formerly known as NovaQuest Capital Management and changed its name to QHP Capital in October 2022. The company was founded in 2010 and is based in Raleigh, North Carolina.

Want to inform investors similar to QHP Capital about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest QHP Capital News
Aug 21, 2023
News provided by Share this article in treating women with severe VVC - Oteseconazole Capsules were found to be safe and more effective than fluconazole - China commercial launch of Oteseconazole Capsules expected in late 2023 DURHAM, N.C., Aug. 21, 2023 /PRNewswire/ -- Mycovia Pharmaceuticals, Inc. ("Mycovia"), an emerging biopharmaceutical company, today announced that Jiangsu Hengrui Pharmaceuticals Co., Ltd ("Hengrui") received approval in June from the National Medical Products Administration for Oteseconazole Capsules, an azole antifungal, indicated for the treatment of severe vulvovaginal candidiasis (VVC). Oteseconazole Capsules is contraindicated for females of reproductive potential, pregnant and lactating women, patients with known hypersensitivity to active ingredients, excipients and azoles. The approval of Oteseconazole Capsules for the treatment of severe VVC in China is an important milestone under Mycovia's exclusive agreement with Hengrui to develop and commercialize oteseconazole in China, including Mainland China, Hong Kong, Macau and Taiwan, for the treatment or prevention of a range of fungal conditions. The approval of Oteseconazole Capsules was based on a Phase 3 study with 322 patients at 27 sites. The primary study endpoint was the proportion of subjects with therapeutic cure (defined as the absence of symptoms and signs of VVC with negative fungal culture candidiasis) at Day 28. In a randomized Phase 3 clinical study to evaluate the efficacy and safety of a two-day dosing regimen of SHR8008 (oteseconazole capsules) versus the current standard-of-care fluconazole in patients with severe VVC, therapeutic cure at Day 28 was significantly higher in the SHR8008 group than in the fluconazole group (66.88% vs 45.91%), p = 0.0002. Mycological cure at Day 28 was higher in the SHR8008 group than in the fluconazole group (82.50% vs 59.12%), p < 0.0001. Therapeutic cure and mycological cure at Day 14 were also statistically superior for subjects receiving SHR8008 compared to those receiving fluconazole. Reported adverse events were similar between treatment groups. "We celebrate and congratulate our partner, Hengrui, on receiving its approval for Oteseconazole Capsules for the treatment of severe VVC," said Patrick Jordan, CEO of Mycovia and Managing Partner at NovaQuest Capital Management. "The disease burden in China is significant and the approval of Oteseconazole Capsules gives another treatment option for those women suffering with VVC." Vulvovaginal candidiasis is an exceedingly common mucosal infection usually caused by Candida albicans but can occasionally be caused by other Candida species or yeasts. Typical symptoms include vulvovaginal itching, irritation, burning, soreness, fissuring, redness, vaginal discharge, and dyspareunia. Approximately 70% to 75% of women in all strata of the society will experience at least one episode during their lifetime. Oteseconazole is designed to selectively inhibit fungal CYP51, which is required for fungal cell wall integrity, and this interaction is also toxic to fungi, resulting in the inhibition of fungal growth. Due to its chemical structure, oteseconazole has a lower affinity for human CYP enzymes as compared to fungal CYP enzymes. In April 2022, the U.S. Food and Drug Administration (FDA) approved VIVJOA® (oteseconazole) Capsules, as the first medication for Recurrent Vulvovaginal Candidiasis (chronic yeast infection). About Recurrent Vulvovaginal Candidiasis RVVC is a debilitating, chronic infectious condition that affects 138 million women worldwide each year. RVVC, also known as chronic yeast infection, is a distinct condition from vulvovaginal candidiasis (VVC) and defined by the Centers for Disease Control and Prevention as three or more symptomatic acute episodes of yeast infection in 12 months. Primary symptoms include vaginal itching, burning, irritation and inflammation. Some women may experience abnormal vaginal discharge and painful sexual intercourse or urination, causing variable but often severe discomfort and pain. About VIVJOA® VIVJOA® (oteseconazole) is an azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are NOT of reproductive potential. VIVJOA is the first FDA-approved medication that provides sustained efficacy demonstrated by significant long-term reduction of RVVC recurrence through 50 weeks versus comparators. Oteseconazole is designed to inhibit fungal CYP51, which is required for fungal cell wall integrity, and this selective interaction is also toxic to fungi, resulting in the inhibition of fungal growth. Due to its chemical structure, oteseconazole has a lower affinity for human CYP enzymes as compared to fungal CYP enzymes. The FDA approved VIVJOA based upon the positive results from three phase 3 clinical trials of oteseconazole – two global VIOLET studies and one U.S.-focused ultraVIOLET study, including 875 patients at 232 sites across 11 countries. Please click here for full Prescribing Information. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS VIVJOA is contraindicated in females of reproductive potential. Females who are NOT of reproductive potential are defined as: persons who are biological females who are postmenopausal or have another reason for permanent infertility (e.g., tubal ligation, hysterectomy, salpingo-oophorectomy). VIVJOA is contraindicated in pregnant and lactating women. VIVJOA is contraindicated in patients with known hypersensitivity to oteseconazole. WARNINGS AND PRECAUTIONS Based on animal studies, VIVJOA may cause fetal harm. The drug exposure window of approximately 690 days (based on 5 times the half-life of oteseconazole) precludes adequate mitigation of the embryo-fetal toxicity risks. Advise patients that VIVJOA is contraindicated in females of reproductive potential, and in pregnant and lactating women because of potential risks to a fetus or breastfed infant. ADVERSE REACTIONS The most frequently reported adverse reactions among VIVJOA-treated patients in clinical studies included headache (7.4%) and nausea (3.6%). DRUG INTERACTIONS VIVJOA is a Breast Cancer Resistance Protein (BCRP) inhibitor. Concomitant use of VIVJOA with BCRP substrates (e.g., rosuvastatin) may increase the exposure of BCRP substrates, which may increase the risk of adverse reactions associated with these drugs. To report SUSPECTED ADVERSE REACTIONS, contact Mycovia Pharmaceuticals, Inc. at 1-855-299-0637 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . About Mycovia Pharmaceuticals, Inc. Mycovia Pharmaceuticals, Inc. is an emerging biopharmaceutical company dedicated to recognizing and empowering those living with unmet medical needs by developing novel therapies. VIVJOA® (oteseconazole) capsules, the first FDA-approved product for Mycovia, is an azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are NOT of reproductive potential. Oteseconazole received FDA Qualified Infectious Disease Product and Fast-Track designations to become the first FDA-approved therapy for RVVC. In 2019, Mycovia licensed oteseconazole to Jiangsu Hengrui Pharmaceuticals Co., Ltd., to develop and commercialize oteseconazole in China, including mainland China, Hong Kong, Macau and Taiwan. Mycovia also recognizes a tremendous potential for its oral fungal inhibitors and a growing need to treat a range of multi-drug resistant fungal pathogens. For more information, please visit www.mycovia.com . About Jiangsu Hengrui Pharmaceuticals Co., Ltd. Hengrui Pharma is a leading global pharmaceutical company headquartered in China with a focus on research, development, manufacturing, and commercialization of innovative and high-quality healthcare products. Innovation is the core development strategy. Hengrui Pharma ranked 21st among the top 1,000 global pharmaceutical companies in 2021.1 Hengrui Pharma has been on the Pharma Exec's annual listing of the top global pharmaceutical companies for the fourth consecutive year, rising from the 47th in 2019 to the 32nd in 2021.2 1. https://torreya.com/publications/pharma-1000-report-torreya-2021-11-08.pdf ; page 49 and 56. 2. https://www.pharmexec.com/view/2022-pharm-exec-top-50-companies ; page 24 About NovaQuest Capital Management Founded by a team of accomplished industry professionals in 2010, NovaQuest Capital Management is a premier biopharma and life sciences investment firm. NovaQuest pioneered a Product Finance solution for the industry, providing at-risk, nondilutive funding that enables partner companies to advance pivotal clinical trials, launch new brands, license products, and acquire accretive products or companies. NovaQuest has invested in scores of biopharmaceutical assets across therapeutic areas with a clinical success rate significantly higher than the industry average. NovaQuest is actively evaluating and investing into global opportunities with financing needs that range from $30-100 million. For more information, please visit www.novaquest.com . SOURCE Mycovia Pharmaceuticals, Inc.
QHP Capital Investments
41 Investments
QHP Capital has made 41 investments. Their latest investment was in COPILOT as part of their Private Equity on January 1, 2023.

QHP Capital Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
1/10/2023 | Private Equity | COPILOT | Yes | 1 | ||
5/25/2022 | Series C | Targan | $35M | Yes | 5 | |
11/30/2021 | Secondary Market | CovenantAH | Yes | 2 | ||
6/8/2021 | Revenue Finance | |||||
5/3/2021 | Series A |
Date | 1/10/2023 | 5/25/2022 | 11/30/2021 | 6/8/2021 | 5/3/2021 |
---|---|---|---|---|---|
Round | Private Equity | Series C | Secondary Market | Revenue Finance | Series A |
Company | COPILOT | Targan | CovenantAH | ||
Amount | $35M | ||||
New? | Yes | Yes | Yes | ||
Co-Investors | |||||
Sources | 1 | 5 | 2 |
QHP Capital Portfolio Exits
15 Portfolio Exits
QHP Capital has 15 portfolio exits. Their latest portfolio exit was Aceragen (acquired by Idera Pharmaceuticals) on September 28, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
9/28/2022 | Acquired | 10 | |||
10/11/2021 | Spinoff / Spinout | QHP Capital | 1 | ||
10/1/2021 | Reverse Merger | 4 | |||
Date | 9/28/2022 | 10/11/2021 | 10/1/2021 | ||
---|---|---|---|---|---|
Exit | Acquired | Spinoff / Spinout | Reverse Merger | ||
Companies | QHP Capital | ||||
Valuation | |||||
Acquirer | |||||
Sources | 10 | 1 | 4 |
QHP Capital Acquisitions
7 Acquisitions
QHP Capital acquired 7 companies. Their latest acquisition was AutoCruitment on October 27, 2022.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
10/27/2022 | Seed / Angel | $0.02M | Acq - Fin | 1 | ||
1/19/2021 | Debt | |||||
11/2/2018 | ||||||
5/14/2018 | Debt | |||||
3/26/2018 | Debt |
Date | 10/27/2022 | 1/19/2021 | 11/2/2018 | 5/14/2018 | 3/26/2018 |
---|---|---|---|---|---|
Investment Stage | Seed / Angel | Debt | Debt | Debt | |
Companies | |||||
Valuation | |||||
Total Funding | $0.02M | ||||
Note | Acq - Fin | ||||
Sources | 1 |
QHP Capital Fund History
11 Fund Histories
QHP Capital has 11 funds, including NovaQuest Private Equity Fund II.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
5/12/2022 | NovaQuest Private Equity Fund II | $500M | 1 | ||
11/5/2019 | NovaQuest Private Equity Fund I | Diversified Private Equity | Closed | $275M | 6 |
6/24/2019 | NovaQuest Pharma Opportunities Fund V | Diversified Private Equity | Open | $892.75M | 5 |
3/8/2019 | NQ PE Project Constellation | ||||
6/29/2018 | NQ PE Project Kit LP |
Closing Date | 5/12/2022 | 11/5/2019 | 6/24/2019 | 3/8/2019 | 6/29/2018 |
---|---|---|---|---|---|
Fund | NovaQuest Private Equity Fund II | NovaQuest Private Equity Fund I | NovaQuest Pharma Opportunities Fund V | NQ PE Project Constellation | NQ PE Project Kit LP |
Fund Type | Diversified Private Equity | Diversified Private Equity | |||
Status | Closed | Open | |||
Amount | $500M | $275M | $892.75M | ||
Sources | 1 | 6 | 5 |
QHP Capital Partners & Customers
4 Partners and customers
QHP Capital has 4 strategic partners and customers. QHP Capital recently partnered with Hansa Biopharma on July 7, 2022.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
7/18/2022 | Vendor | Sweden | Hansa Biopharma AB and NovaQuest Capital Management have also entered into a security agreement to provide NovaQuest Capital Management a customary security interest in and lien upon right , title and interest in certain of Hansa Biopharma AB 's assets and IP . | 1 | |
3/29/2022 | Partner | ||||
3/29/2022 | Partner | ||||
5/14/2018 | Partner |
Date | 7/18/2022 | 3/29/2022 | 3/29/2022 | 5/14/2018 |
---|---|---|---|---|
Type | Vendor | Partner | Partner | Partner |
Business Partner | ||||
Country | Sweden | |||
News Snippet | Hansa Biopharma AB and NovaQuest Capital Management have also entered into a security agreement to provide NovaQuest Capital Management a customary security interest in and lien upon right , title and interest in certain of Hansa Biopharma AB 's assets and IP . | |||
Sources | 1 |
QHP Capital Service Providers
1 Service Provider
QHP Capital has 1 service provider relationship
Service Provider | Associated Rounds | Provider Type | Service Type |
---|---|---|---|
Private Equity, and Acq - Fin | Counsel | General Counsel |
Service Provider | |
---|---|
Associated Rounds | Private Equity, and Acq - Fin |
Provider Type | Counsel |
Service Type | General Counsel |
Partnership data by VentureSource
QHP Capital Team
4 Team Members
QHP Capital has 4 team members, including current Chief Financial Officer, Robert Hester.
Name | Work History | Title | Status |
---|---|---|---|
Robert Hester | Chief Financial Officer | Current | |
Name | Robert Hester | |||
---|---|---|---|---|
Work History | ||||
Title | Chief Financial Officer | |||
Status | Current |
Compare QHP Capital to Competitors

Pagan Research is an online B2B database and business intelligence website. It delivers quality data for the US, Asia, and EU regions' startups, recent fundings, exits, and more. The company was founded in 2016 and is based in Boston, Massachusetts.
ElexoPharm is a German biotech company, founded as a spin-off of the Department of Pharmaceutical and Medicinal Chemistry of Saarland University. ElexoPharm is focused on the preclinical discovery and optimization of drugs for human diseases, which are currently not or insufficiently treatable with existing drugs.

Sai Life Sciences offers their clients a wide range of integrated drug discovery, development and formulation services, with core expertise founded in synthetic, medicinal and process chemistry and further augmented by a suite of preclinical support services including DMPK, toxicology and formulation that are continually expanding to meet clients' needs.
Ardent Health Services, previously known as Behavioral Healthcare, invests in people, technology, facilities, and communities, producing high-quality care and extraordinary results. Ardent currently operates three health systems with a range of hospitals and employs multi-specialty physicians in multiple clinic locations across New Mexico, Oklahoma, and Texas. The company was founded in 1993 and is based in Nashville, Tennessee.
Veratect offers services that aim to offer the early detection, 24/7 tracking and actionable alert generation of emerging threats (pandemics) worldwide. The company offers the Foreshadow and VeraSight. Per the company, Veratect provides timely and actionable information that supports informed decisions across a broad range of public and private institutions. By identifying emerging risks early, Veratect contends that actions can be taken that save human life, enable loss control, preserve business processes, safeguard supply chain operations and facilities, better manage financial reporting and insurance coverage, and mitigate potential class action lawsuits due to negligence in responding to threats in a timely manner.

Blaze Systems is a provider of total LIMS software solutions for the laboratory marketplace.